<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: Additional ", fill: "#fe4eda"},
{source: "5: Additional ", target: "5: uncertainties", fill: "#fe4eda"},
{source: "5: uncertainties", target: "5: presently known", fill: "#fe4eda"},
{source: "5: presently known", target: "5: Contents ", fill: "#fe4eda"},
{source: "5: Contents ", target: "5: immaterial also may impair", fill: "#fe4eda"},
{source: "5: immaterial also may impair", target: "5: operations", fill: "#fe4eda"},
{source: "5: Additional ", target: "10: loss applicable", fill: "#dda0dd"},
{source: "10: loss applicable", target: "10: stockholders", fill: "#dda0dd"},
{source: "10: stockholders", target: "10: nonrecurring adjustment", fill: "#dda0dd"},
{source: "10: nonrecurring adjustment", target: "10: adjustment recorded as", fill: "#dda0dd"},
{source: "10: adjustment recorded as", target: "10: deconsolidation", fill: "#dda0dd"},
{source: "10: deconsolidation", target: "10: Codexis ", fill: "#dda0dd"},
{source: "10: loss applicable", target: "17: collaborations", fill: "#673147"},
{source: "17: collaborations", target: "17: existing agreements", fill: "#673147"},
{source: "17: existing agreements", target: "17: generally", fill: "#673147"},
{source: "17: generally", target: "17: terminated under certain conditions", fill: "#673147"},
{source: "17: terminated under certain conditions", target: "17: secure future agreements will depend upon", fill: "#673147"},
{source: "17: secure future agreements will depend upon", target: "17: potential future collaborators", fill: "#673147"},
{source: "17: collaborations", target: "18: spend significant amounts", fill: "#2c1608"},
{source: "18: spend significant amounts", target: "18: development", fill: "#2c1608"},
{source: "18: development", target: "18: product candidates", fill: "#2c1608"},
{source: "18: spend significant amounts", target: "22: commercially", fill: "#008080"},
{source: "22: commercially", target: "22: operations", fill: "#008080"},
{source: "22: commercially", target: "24: commercial development", fill: "#000080"},
{source: "24: commercial development", target: "25: Successful ", fill: "#009e60"},
{source: "25: Successful ", target: "25: products will", fill: "#009e60"},
{source: "25: products will", target: "25: significant development", fill: "#009e60"},
{source: "25: significant development", target: "25: investment", fill: "#009e60"},
{source: "25: investment", target: "25: demonstrate", fill: "#009e60"},
{source: "25: demonstrate", target: "25: effectiveness", fill: "#009e60"},
{source: "25: effectiveness", target: "25: commercialization", fill: "#009e60"},
{source: "25: Successful ", target: "64: potential products involve", fill: "#0067a5"},
{source: "64: potential products involve", target: "64: application", fill: "#0067a5"},
{source: "64: application", target: "64: new technologies", fill: "#0067a5"},
{source: "64: new technologies", target: "64: based upon new therapeutic approaches", fill: "#0067a5"},
{source: "64: based upon new therapeutic approaches", target: "64: government", fill: "#0067a5"},
{source: "64: government", target: "64: regulatory", fill: "#0067a5"},
{source: "64: regulatory", target: "64: authorities", fill: "#0067a5"},
{source: "64: authorities", target: "64: authorities may grant regulatory approvals", fill: "#0067a5"},
{source: "64: authorities may grant regulatory approvals", target: "64: products than", fill: "#0067a5"},
{source: "64: products than", target: "64: products using", fill: "#0067a5"},
{source: "64: products using", target: "64: conventional technologies", fill: "#0067a5"},
{source: "64: potential products involve", target: "93: proprietary research programs", fill: "#a81c07"},
{source: "93: proprietary research programs", target: "93: conflicts with", fill: "#a81c07"},
{source: "93: conflicts with", target: "93: collaborators", fill: "#a81c07"},
{source: "93: collaborators", target: "93: inability", fill: "#a81c07"},
{source: "93: inability", target: "93: commercialize products", fill: "#a81c07"},
{source: "93: commercialize products", target: "93: research could harm", fill: "#a81c07"},
{source: "93: proprietary research programs", target: "107: inability", fill: "#696969"},
{source: "107: inability", target: "107: adequately protect", fill: "#696969"},
{source: "107: adequately protect", target: "107: proprietary technologies could harm", fill: "#696969"},
{source: "107: proprietary technologies could harm", target: "107: competitive position", fill: "#696969"},
{source: "107: inability", target: "108: intellectual property", fill: "#e49b0f"},
{source: "108: intellectual property", target: "108: technologies", fill: "#e49b0f"},
{source: "108: technologies", target: "108: United States ", fill: "#e49b0f"},
{source: "108: intellectual property", target: "START_HERE", fill: "#e49b0f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Data Processing Services</td>
    </tr>
    <tr>
      <td>Data Processing and Outsourced Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MAXYGEN INC      Item 1A RISK FACTORS          This report contains forward-looking statements that <font color="blue">involve risks</font> and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our  actual results <font color="blue">could differ materially from</font> those     anticipated in these forward-looking statements as a result of <font color="blue">factors both</font>     in and out of our control, including the <font color="blue">risks faced by us described</font> below     and elsewhere in this report</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below, <font color="blue">together with</font> all     of  the  other information included in this report, in considering our     business and prospects</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> described below are not     the <font color="blue">only ones facing</font> our company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not     <font color="blue">presently known</font> to us or that we currently                                            14     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>deem <font color="blue">immaterial also may impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the     <font color="blue">following risks actually</font> occur, our business could be harmed</td>
    </tr>
    <tr>
      <td>In such case,     the <font color="blue">trading price</font> of our <font color="blue">common <font color="blue">stock could decline</font></font>, and you may lose all or     part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur net losses</font>     and may not achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have incurred losses since our inception, including a <font color="blue">loss applicable</font> to     common  <font color="blue">stockholders</font>  of  dlra35dtta2  million  in  2005,  before a positive     non-recurring adjustment of dlra16dtta6 million resulting from the cumulative     effect <font color="blue">adjustment recorded as</font> a result of the <font color="blue">deconsolidation</font> of Codexis,     and dlra33dtta7 million in 2003</td>
    </tr>
    <tr>
      <td>During 2004, we recognized <font color="blue">income applicable</font> to     common <font color="blue">stockholders</font> of dlra8dtta3 million, primarily due to the sale of Verdia,     but our loss from continuing <font color="blue">operations</font> was dlra49dtta1 million</td>
    </tr>
    <tr>
      <td>Our loss from     continuing <font color="blue">operations</font> in 2005 was dlra35dtta1 million</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we     had an <font color="blue">accumulated deficit</font> of dlra204dtta2 million</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur net losses</font>     and <font color="blue">negative cash flow from</font> operating <font color="blue">activities</font> for at least the next     several  years</td>
    </tr>
    <tr>
      <td>The  funded  research  portion  of one of our primary     <font color="blue"><font color="blue">collaboration</font>s</font>, with Roche for our MAXY-alpha <font color="blue">product <font color="blue">candidates</font></font>, ended in     <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>To date, we have derived <font color="blue">substantially</font> all our <font color="blue">revenues from</font>     <font color="blue"><font color="blue">collaboration</font>s</font> and grants and expect to derive a substantial majority of our     <font color="blue">revenue from such sources</font> for at least the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>Revenues from     <font color="blue"><font color="blue">collaboration</font>s</font> and grants are uncertain because our <font color="blue">existing <font color="blue">agreement</font>s</font>     <font color="blue">generally</font> have fixed terms and may be <font color="blue">terminated under certain <font color="blue">conditions</font></font>,     and because our ability to <font color="blue">secure future <font color="blue">agreement</font>s will depend upon</font> our     ability to address the needs of current and <font color="blue">potential future <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>We  expect to <font color="blue">spend <font color="blue">significant</font> amounts</font> to fund the <font color="blue">development</font> of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>As a result, we expect that our operating expenses will     exceed  revenues  in  the  near  term  and we do not expect to achieve     <font color="blue">profitability</font> during the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>If the time required for us to     achieve <font color="blue">profitability</font> is <font color="blue">longer than</font> we anticipate, we may not be able to     continue our business</td>
    </tr>
    <tr>
      <td>We are an <font color="blue">early stage company deploying <font color="blue">unproven <font color="blue">technologies</font></font></font></td>
    </tr>
    <tr>
      <td>If we do not     develop  <font color="blue">commercially</font>  successful  products, we may be forced to cease     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You  must  evaluate  us in light of the <font color="blue">uncertainties</font> and <font color="blue">complexities</font>     <font color="blue">affecting</font> an <font color="blue">early stage <font color="blue">bio<font color="blue">technology</font></font> company</font></td>
    </tr>
    <tr>
      <td>We may not be successful in     the commercial <font color="blue">development</font> of products</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">products will</font> require     <font color="blue">significant</font> <font color="blue">development</font> and <font color="blue">investment</font>, including testing, to <font color="blue">demonstrate</font>     their safety and <font color="blue"><font color="blue">effective</font>ness</font> before their <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>To date,     companies in the <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> industry</font> have developed and <font color="blue"><font color="blue">commercialize</font>d</font>     only a limited number of products</td>
    </tr>
    <tr>
      <td>We have not proven our ability to develop     or <font color="blue">commercialize</font> any products</td>
    </tr>
    <tr>
      <td>We, <font color="blue">either alone</font> or in <font color="blue">conjunction with</font> our     corporate <font color="blue">collaborators</font>, must conduct a substantial amount of <font color="blue">additional</font>     research and <font color="blue">development</font> before any <font color="blue"><font color="blue">regulatory</font> authority will approve</font> any of     our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>This research and <font color="blue">development</font> may not indicate that     our products are safe and <font color="blue">effective</font>, in <font color="blue">which case <font color="blue">regulatory</font> <font color="blue">authorities</font></font>     may not <font color="blue">approve them</font></td>
    </tr>
    <tr>
      <td>Problems <font color="blue">frequently <font color="blue">encountered</font></font> in <font color="blue">connection with</font> the     <font color="blue">development</font>  and  <font color="blue">utilization</font> of new and <font color="blue">unproven <font color="blue">technologies</font></font> and the     <font color="blue">competitive environment</font> in which we operate <font color="blue">could limit</font> our ability to     develop <font color="blue">commercially</font> successful products</td>
    </tr>
    <tr>
      <td>Our revenues, expenses and operating results are subject to <font color="blue">fluctuations</font>     that may cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our revenues, expenses and operating results have fluctuated in the past and     are likely to do so in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> could cause our stock     price to <font color="blue">fluctuate <font color="blue"><font color="blue">significant</font>ly</font></font> or decline</td>
    </tr>
    <tr>
      <td>Some of the factors that could     cause our revenues, expenses and operating results to fluctuate include:           ·   <font color="blue">termination</font> of <font color="blue"><font color="blue">research contracts</font> with <font color="blue">collaborators</font></font> or <font color="blue">government</font>     research grants, which may not be renewed or replaced;           ·   the <font color="blue">success rate</font> of our <font color="blue">development</font> or <font color="blue"><font color="blue">discovery</font> efforts leading</font> to     <font color="blue">milestones</font> and royalties;           ·   timing of <font color="blue">licensing fees</font> or the <font color="blue">achievement</font> of <font color="blue">milestones</font> under new or     <font color="blue">existing licensing</font> and <font color="blue"><font color="blue">collaborative</font> arrangements</font>;                                           15     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>  ·   timing of expenses, particularly with respect to contract     <font color="blue">manufacturing</font>, pre-clinical studies and <font color="blue">clinical trials</font>;           ·   the timing and <font color="blue">willingness</font> of <font color="blue">collaborators</font> to <font color="blue">commercialize</font> our     products, which would result in royalties to us; and           ·   general and industry specific economic <font color="blue">conditions</font>, which may affect     our <font color="blue">collaborators</font>’ research and <font color="blue">development</font> <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>A large portion of our expenses are <font color="blue">relatively</font> fixed, including expenses for     <font color="blue">facilities</font>, equipment and personnel</td>
    </tr>
    <tr>
      <td>Accordingly, if <font color="blue">revenues fluctuate</font>     unexpectedly  due  to  unexpected  expiration of <font color="blue">research contracts</font> or     <font color="blue">government</font> research grants, failure to obtain anticipated <font color="blue">new contracts</font> or     other  factors, we may not be able to <font color="blue">immediately reduce</font> our operating     expenses</td>
    </tr>
    <tr>
      <td>Failure to achieve anticipated levels of revenues could therefore     <font color="blue"><font color="blue">significant</font>ly</font> harm our operating results for a <font color="blue">particular fiscal period</font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">possibility</font> of <font color="blue">fluctuations</font> in our revenues and expenses, we     believe that quarter-to-quarter comparisons of our operating results are not     a good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Our operating results in some     quarters  may  not  meet the <font color="blue">expectations</font> of <font color="blue">stock market analysts</font> and     investors</td>
    </tr>
    <tr>
      <td>In that case, our <font color="blue">stock price would likely decline</font></td>
    </tr>
    <tr>
      <td>Our  revenues  are  <font color="blue">substantially</font>  <font color="blue">dependent</font>  on  a  limited number of     <font color="blue"><font color="blue">collaborative</font> arrangements</font> and <font color="blue">government</font> grants, and our <font color="blue">inability</font> to     maintain   existing  <font color="blue"><font color="blue">collaboration</font>s</font>  or  grants  or  establish  future     <font color="blue"><font color="blue">collaboration</font>s</font> or <font color="blue">grants would <font color="blue">adversely</font> impact</font> our revenues, financial     position and results of operation</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">substantially</font> all of our revenue for the <font color="blue">foreseeable future</font>     will result from payments under our <font color="blue"><font color="blue">collaborative</font> arrangements</font> and from     <font color="blue">government</font> grants</td>
    </tr>
    <tr>
      <td>We currently have one <font color="blue">collaboration</font> <font color="blue">agreement</font>, with <font color="blue">Roche     </font>for our MAXY-VII <font color="blue">product <font color="blue">candidates</font></font>, and three <font color="blue">government</font> grants that are     expected to <font color="blue">generate revenue</font> in 2006</td>
    </tr>
    <tr>
      <td>If this <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font> with</font>     Roche  is not successful or the <font color="blue">agreement</font> or the <font color="blue">government</font> grants are     terminated and we are unable to enter into new <font color="blue">collaboration</font> <font color="blue">agreement</font>s or     secure <font color="blue">additional</font> grants, our revenues, financial position and results of     <font color="blue">operations</font> would be <font color="blue">materially <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Drug <font color="blue">development</font> is a long, expensive and <font color="blue">uncertain process</font> and may not     result in the <font color="blue">development</font> of any <font color="blue">commercially</font> successful products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue">human <font color="blue">therapeutic</font> products</font> is long and uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Most     </font><font color="blue">product <font color="blue">candidates</font></font> fail before entering <font color="blue">clinical trials</font> and most clinical     trials do not result in a <font color="blue">marketed product</font></td>
    </tr>
    <tr>
      <td>In addition, due to the nature     of  <font color="blue">human <font color="blue">therapeutic</font> research</font> and <font color="blue">development</font>, the expected timing of     product <font color="blue">development</font> and <font color="blue">initiation</font> of <font color="blue">clinical trials</font> and the results of     such <font color="blue">development</font> and <font color="blue">clinical trials</font> are uncertain and subject to change at     any point</td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">uncertainty</font> may</font> result in research delays, product candidate     failures and <font color="blue">clinical trial delays</font> and failures</td>
    </tr>
    <tr>
      <td>Such delays and failures     <font color="blue">could drastically reduce</font> the price of our stock and our ability to raise     capital</td>
    </tr>
    <tr>
      <td>Without <font color="blue">sufficient capital</font>, we would need to reduce <font color="blue">operations</font> and     could be forced to cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we may determine that certain preclinical <font color="blue">product <font color="blue">candidates</font></font> or     programs  do not have <font color="blue">sufficient potential</font> to <font color="blue">warrant further funding</font></td>
    </tr>
    <tr>
      <td>Accordingly,  we  may elect to terminate our programs for <font color="blue">such product</font>     <font color="blue">candidates</font> or <font color="blue">programs at</font> any time</td>
    </tr>
    <tr>
      <td>If we terminate a <font color="blue">preclinical program</font> in     which we have <font color="blue">invested <font color="blue">significant</font> resources</font>, our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font> may be <font color="blue">adversely</font> affected, as we will have expended     <font color="blue">resources on</font> a program that will not provide a return on our <font color="blue">investment</font> and     we will have missed the <font color="blue">opportunity</font> to have allocated those resources to     <font color="blue">potentially</font> more <font color="blue">productive uses</font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of such programs could cause     the price of our stock to drop <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential products</font> are subject to a lengthy and <font color="blue">uncertain <font color="blue">regulatory</font></font>     process</td>
    </tr>
    <tr>
      <td>If our <font color="blue">potential products</font> are not approved, we will not be able to     <font color="blue">commercialize</font> those products</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">must approve</font> any <font color="blue">therapeutic</font> product or vaccine before it can be     marketed in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Before we can file a <font color="blue">new drug <font color="blue">application</font></font> or     <font color="blue">biologic license <font color="blue">application</font> with</font> the FDA, the product candidate                                           16     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font><font color="blue">must undergo</font> extensive testing, including animal and human <font color="blue">clinical trials</font>,     which  can  take many years and require substantial <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Data     </font>obtained <font color="blue">from such testing</font> are susceptible to <font color="blue">varying interpretations</font> that     could delay, limit or <font color="blue">prevent <font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>In addition, changes in     <font color="blue">regulatory</font>  policy  for  <font color="blue">product approval</font> during the period of product     <font color="blue">development</font> and <font color="blue">regulatory</font> agency review of <font color="blue">each submitted new <font color="blue">application</font></font>     or  product  license  <font color="blue">application</font>  may cause delays or <font color="blue">rejections</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">regulatory</font> process is expensive and time consuming</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> agencies     of foreign <font color="blue">government</font>s must also approve our <font color="blue">therapeutic</font> products before the     products can be sold in those other countries</td>
    </tr>
    <tr>
      <td>Because our <font color="blue">potential products</font> involve the <font color="blue">application</font> of <font color="blue">new <font color="blue">technologies</font></font>     and may be <font color="blue">based upon new <font color="blue">therapeutic</font> approaches</font>, they may be subject to     substantial  review  by  <font color="blue">government</font>  <font color="blue">regulatory</font>  <font color="blue">authorities</font> and these     <font color="blue">authorities</font> may grant <font color="blue">regulatory</font> approvals more slowly for our <font color="blue">products than</font>     for <font color="blue">products using</font> more <font color="blue">conventional <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>We have not submitted an     <font color="blue">application</font> to the FDA or any other <font color="blue">regulatory</font> authority for any product     candidate,  and neither the FDA nor any other <font color="blue">regulatory</font> authority has     approved   any   <font color="blue">therapeutic</font>  product  candidate  developed  with  our     <font color="blue">MolecularBreeding </font><font color="blue">directed evolution platform</font> for <font color="blue">commercialization</font> in the     <font color="blue">United States</font> or elsewhere</td>
    </tr>
    <tr>
      <td>We may not be able to, or our <font color="blue">collaborators</font> may     not be able to, <font color="blue">conduct clinical testing</font> or obtain the <font color="blue"><font color="blue">necessary</font> approvals</font>     from the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> for our products</td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue">regulatory</font> approval, this <font color="blue">approval may entail limitations</font>     on the <font color="blue">indicated uses</font> for which we can market a product</td>
    </tr>
    <tr>
      <td>Further, once     <font color="blue">regulatory</font> approval is obtained, a <font color="blue">marketed product</font> and its <font color="blue"><font color="blue">manufacture</font>r</font> are     subject to <font color="blue">continual review</font>, and <font color="blue">discovery</font> of <font color="blue">previously unknown problems</font>     with a product or <font color="blue"><font color="blue">manufacture</font>r</font> may result in <font color="blue"><font color="blue">restrictions</font> on</font> the product,     <font color="blue"><font color="blue">manufacture</font>r</font> or <font color="blue"><font color="blue">manufacturing</font> facility</font>, including withdrawal of the product     from the market</td>
    </tr>
    <tr>
      <td>In certain countries, <font color="blue">regulatory</font> agencies also set or     <font color="blue">approve prices</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacturing</font>  of  our <font color="blue">product <font color="blue">candidates</font></font> presents technological,     logistical and <font color="blue">regulatory</font> risks, each of <font color="blue">which may <font color="blue">adversely</font> affect</font> our     <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font> and <font color="blue">manufacturing</font> <font color="blue">development</font> of <font color="blue">pharmaceuticals</font>, and, in     particular, biologicals, are <font color="blue">technologically</font> and <font color="blue">logistically complex</font> and     heavily  regulated  by the FDA and other <font color="blue">government</font>al <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">manufacturing</font>  and <font color="blue">manufacturing</font> <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font>     present many risks, including, but not limited to, the following:           ·   before we can obtain approval of any of our products or product     <font color="blue">candidates</font> for the treatment of a <font color="blue">particular disease</font> or condition, we must     <font color="blue">demonstrate</font> to the <font color="blue">satisfaction</font> of the FDA and other <font color="blue">government</font>al     <font color="blue">authorities</font> that the <font color="blue">drug <font color="blue">manufacture</font>d</font> for the <font color="blue">clinical trials</font> is comparable     to the <font color="blue">drug <font color="blue">manufacture</font>d</font> for <font color="blue">commercial use</font> and that the <font color="blue">manufacturing</font>     <font color="blue">facility complies with applicable laws</font> and <font color="blue">regulations</font>;           ·   it may not be <font color="blue">technically feasible</font> to scale up an existing     <font color="blue">manufacturing</font> process to meet demand or such scale-up may take <font color="blue">longer than</font>     anticipated; and           ·   failure to <font color="blue"><font color="blue">comply with</font> strictly enforced</font> GMP <font color="blue">regulations</font> and similar     <font color="blue">foreign standards may</font> result in delays in <font color="blue">product approval</font> or withdrawal of     an <font color="blue">approved product from</font> the market</td>
    </tr>
    <tr>
      <td>Any of these factors could delay any <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> <font color="blue">submissions</font>     or <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font>, entail higher costs and     result in our being unable to <font color="blue">effective</font>ly sell any products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> strategy, which relies on third-party <font color="blue"><font color="blue">manufacture</font>r</font>s,     <font color="blue">exposes us</font> to <font color="blue">additional</font> risks</td>
    </tr>
    <tr>
      <td>We  do  not  currently have the resources, <font color="blue">facilities</font> or experience to     <font color="blue">manufacture</font>  any  product  <font color="blue">candidates</font> or <font color="blue">potential products</font> ourselves</td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of any <font color="blue">clinical trials</font> and any <font color="blue">commercialization</font> of our products     will require access to, or <font color="blue">development</font> of, <font color="blue">manufacturing</font> <font color="blue">facilities</font> that     meet  FDA  standards or other <font color="blue">regulatory</font> <font color="blue">requirements</font> to <font color="blue">manufacture</font> a     <font color="blue">sufficient supply</font> of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently depend on third</font>     parties for the scale up and <font color="blue">manufacture</font> of our <font color="blue">product <font color="blue">candidates</font></font> for     preclinical and <font color="blue">clinical purposes</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">third party</font> <font color="blue"><font color="blue">manufacture</font>r</font>s are     unable to <font color="blue">manufacture</font> preclinical or <font color="blue">clinical supplies</font> in a <font color="blue">timely manner</font>,     or are unable or                                           17     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>unwilling to satisfy our needs or FDA or other <font color="blue">regulatory</font> <font color="blue">requirements</font>, it     could delay <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> <font color="blue">submissions</font> and <font color="blue">commercialization</font> of     our <font color="blue">potential products</font>, entail higher costs and possibly result in our being     unable  to sell our products</td>
    </tr>
    <tr>
      <td>In addition, technical problems or other     <font color="blue">manufacturing</font> delays could delay the <font color="blue">advancement</font> of <font color="blue">potential products</font> into     preclinical or <font color="blue">clinical trials</font> or result in the <font color="blue">termination</font> of <font color="blue">development</font>     of  particular  product  <font color="blue">candidates</font>,  <font color="blue">adversely</font>  <font color="blue">affecting</font> our product     <font color="blue">development</font> timetable, which in turn could <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td>In addition, failure of any <font color="blue">third party</font> <font color="blue"><font color="blue">manufacture</font>r</font>s or us to <font color="blue">comply with</font>     applicable <font color="blue">regulations</font>, including pre- or post-approval inspections and the     GMP <font color="blue">requirements</font> of the FDA or other comparable <font color="blue">regulatory</font> agencies, could     result in sanctions being <font color="blue">imposed on us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">sanctions could</font> include     fines, injunctions, civil penalties, failure of <font color="blue">regulatory</font> <font color="blue">authorities</font> to     <font color="blue">grant marketing approval</font> of our products, delay, suspension or withdrawal of     approvals, license revocation, product seizures or recalls, operational     <font color="blue">restrictions</font> and <font color="blue">criminal prosecutions</font>, any of <font color="blue">which could</font> <font color="blue"><font color="blue">significant</font>ly</font> and     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">collaboration</font>s</font> are not successful, we may not be able to <font color="blue">effective</font>ly     develop and market some of our products</td>
    </tr>
    <tr>
      <td>Since we do not currently possess the resources <font color="blue">necessary</font> to develop and     <font color="blue">commercialize</font> multiple products, or the resources to complete all approval     processes that may be required for these <font color="blue">potential products</font>, we <font color="blue">generally</font>     seek to enter into <font color="blue"><font color="blue">collaborative</font> arrangements</font> to develop and <font color="blue">commercialize</font>     <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We have entered into <font color="blue">collaborative</font> <font color="blue">agreement</font>s with other     companies to fund the <font color="blue">development</font> of <font color="blue">new products</font> for <font color="blue">specific purposes</font></td>
    </tr>
    <tr>
      <td>These contracts <font color="blue">generally</font> expire after a fixed period of time</td>
    </tr>
    <tr>
      <td>If they are     not renewed or if we do not enter into new <font color="blue">collaborative</font> <font color="blue">agreement</font>s, our     revenues  will  be  reduced  and  our  potential  products  may not be     <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>We have limited or <font color="blue">no control over</font> the resources that any <font color="blue">collaborator may</font>     devote to the <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Any of our present or future <font color="blue">collaborators</font> may not perform their <font color="blue">obligations</font>     as  expected</td>
    </tr>
    <tr>
      <td>These  <font color="blue">collaborators</font>  may  delay  such  <font color="blue">development</font>  or     <font color="blue">commercialization</font>, breach or terminate their <font color="blue">agreement</font> with us or otherwise     fail to conduct their <font color="blue">collaborative</font> <font color="blue">activities</font> <font color="blue">successfully</font> and in a timely     manner</td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">collaborators</font> may elect not to develop potential     products arising out of our <font color="blue"><font color="blue">collaborative</font> arrangements</font> or <font color="blue">devote sufficient</font>     resources  to the <font color="blue">development</font>, <font color="blue">manufacture</font>, marketing or sale of these     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not be able to develop or     <font color="blue">commercialize</font> our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>In  particular,  we  have  entered  into <font color="blue">agreement</font>s with Roche for the     co-<font color="blue">development</font> and <font color="blue">commercialization</font> of two of our lead <font color="blue">product <font color="blue">candidates</font></font>,     MAXY-alpha and MAXY-VII The failure of Roche to perform its <font color="blue">obligations</font>     under either <font color="blue">agreement</font>, our failure to perform our <font color="blue">obligations</font> under either     <font color="blue">agreement</font>  or  to <font color="blue">effective</font>ly manage our <font color="blue">relationship</font> with Roche, or a     material <font color="blue">contractual dispute with</font> Roche under either <font color="blue">agreement</font> would have a     material adverse effect on our prospects and financial results</td>
    </tr>
    <tr>
      <td>We  conduct  <font color="blue"><font color="blue">proprietary</font> research programs</font>, and any <font color="blue">conflicts with</font> our     <font color="blue">collaborators</font> or any <font color="blue">inability</font> to <font color="blue">commercialize</font> products resulting from this     <font color="blue">research could harm</font> our business</td>
    </tr>
    <tr>
      <td>An important part of our <font color="blue">strategy involves conducting <font color="blue">proprietary</font> research</font>     programs</td>
    </tr>
    <tr>
      <td>As a result, we may pursue <font color="blue">opportunities</font> in fields that could     <font color="blue">conflict with</font> those of our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Moreover, dis<font color="blue">agreement</font>s with our     <font color="blue">collaborators</font> could develop <font color="blue">over rights</font> to our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">conflict with</font> our <font color="blue">collaborators</font> could reduce our ability to obtain future     <font color="blue">collaboration</font>  <font color="blue">agreement</font>s  and <font color="blue">negatively impact</font> our <font color="blue">relationship</font> with     existing <font color="blue">collaborators</font>, <font color="blue">which could</font> reduce our revenues</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">collaborators</font> could become our <font color="blue">competitors</font> in the future</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> could develop <font color="blue">competing products</font>, preclude us from entering     into <font color="blue"><font color="blue"><font color="blue">collaboration</font>s</font> with</font> their <font color="blue">competitors</font>, fail to obtain timely <font color="blue">regulatory</font>     approvals, terminate their <font color="blue">agreement</font>s with us prematurely or fail to devote     <font color="blue">sufficient resources</font> to                                           18     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>allow the <font color="blue">development</font> and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Any of these     <font color="blue">development</font>s could harm our product <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>In some cases, our <font color="blue">collaborators</font> already market a product that could be     <font color="blue">competitive with</font> the product(s) that we are <font color="blue">collaborating with them on</font> for     an <font color="blue">improved version</font>, and <font color="blue">could conduct</font> their <font color="blue">operations</font> in a manner that     <font color="blue">discriminates against</font> the product that we developed</td>
    </tr>
    <tr>
      <td>We  will  either <font color="blue">commercialize</font> products resulting from our <font color="blue">proprietary</font>     programs  directly or <font color="blue">through licensing</font> to other companies</td>
    </tr>
    <tr>
      <td>We have no     experience in <font color="blue">manufacturing</font> or marketing, and we currently do not have the     resources or <font color="blue">capability</font> to <font color="blue">manufacture</font> products on a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>In     order for us to <font color="blue">commercialize</font> these <font color="blue">products directly</font>, we would need to     develop, or obtain <font color="blue">through outsourcing arrangements</font>, the <font color="blue">capability</font> to     <font color="blue">manufacture</font>,  market  and  sell  products, each of <font color="blue">which could</font> require     <font color="blue">significant</font> capital <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We do not have these <font color="blue">capabilities</font>, and we     may not be able to develop or otherwise obtain the requisite <font color="blue">manufacturing</font>,     marketing  and  sales  <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font>     <font color="blue">commercialize</font> products resulting from our <font color="blue">proprietary</font> research efforts, we     <font color="blue">will continue</font> to <font color="blue">incur losses</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to <font color="blue">adequately protect</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font> could harm     our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Our  success  will depend in part on our ability to obtain patents and     maintain  adequate  protection  of  our  <font color="blue"><font color="blue">intellectual</font> property</font> for our     <font color="blue">technologies</font> and products in the <font color="blue">United States</font> and other countries</td>
    </tr>
    <tr>
      <td>If we do     not <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font>, <font color="blue">competitors</font> may be able to     practice our <font color="blue">technologies</font> and erode our <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>The laws of     some foreign countries do not protect <font color="blue">proprietary</font> rights to the <font color="blue">same extent</font>     as  the laws of the <font color="blue">United States</font>, and many companies have <font color="blue">encountered</font>     <font color="blue">significant</font> problems in protecting their <font color="blue">proprietary</font> rights in these foreign     countries</td>
    </tr>
    <tr>
      <td>These problems can be caused by, for example, a lack of rules and     <font color="blue">processes allowing</font> for meaningfully defending <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>We will be able to protect our <font color="blue">proprietary</font> rights from unauthorized use by     <font color="blue"><font color="blue">third parties</font> only</font> to the extent that our <font color="blue">proprietary</font> <font color="blue">technologies</font> are     <font color="blue">covered by valid</font> and <font color="blue">enforceable patents</font> or are <font color="blue">effective</font>ly maintained as     <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">biopharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, including our <font color="blue">patent positions</font>, are <font color="blue">often uncertain</font> and involve     <font color="blue">complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>We apply for <font color="blue">patents covering</font> our     <font color="blue">technologies</font> and <font color="blue">potential products</font> as we deem <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>However, we may     not obtain patents on all <font color="blue">inventions</font> for which we <font color="blue">seek patents</font>, and any     patents  we  obtain  may be challenged and may be narrowed in scope or     <font color="blue">extinguished as</font> a result of <font color="blue">such <font color="blue">challenges</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing patents</font> and any     <font color="blue">future patents</font> we obtain may not be <font color="blue">sufficiently broad</font> to <font color="blue">prevent others</font>     from practicing our <font color="blue">technologies</font> or from developing <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Enforcement </font>of our patents against <font color="blue">infringers</font> could require us to expend     <font color="blue">significant</font> amounts with no assurance that we would be successful in any     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Others  may  in<font color="blue">dependent</font>ly develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font> or <font color="blue">design around</font> our patented <font color="blue">technologies</font> or products</td>
    </tr>
    <tr>
      <td>In     addition, others may challenge or invalidate our patents, or our <font color="blue">patents may</font>     fail to <font color="blue">provide us with</font> any <font color="blue">competitive advantage</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely upon trade secret protection</font> for our <font color="blue">confidential</font> and <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>We have <font color="blue">taken security measures</font> to protect our <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>These <font color="blue">measures may</font> not <font color="blue">provide adequate protection</font> for our     <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>We seek to protect our     <font color="blue">proprietary</font> information by entering into <font color="blue">confidential</font>ity <font color="blue">agreement</font>s with     employees,  <font color="blue">collaborators</font>  and  <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Nevertheless, employees,     <font color="blue">collaborators</font> or <font color="blue">consultants</font> may still disclose or misuse our <font color="blue">proprietary</font>     information,  and we may not be able to <font color="blue">meaningfully protect</font> our trade     secrets</td>
    </tr>
    <tr>
      <td>In  addition, others may in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> information or <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to     our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation  </font>or other <font color="blue">proceedings</font> or <font color="blue">third party</font> claims of <font color="blue">intellectual</font>     <font color="blue">property infringement could</font> require us to spend time and money and could     require us to shut down some of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to develop products depends in part on not <font color="blue">infringing patents</font> or     other <font color="blue">proprietary</font> rights of <font color="blue">third parties</font>, and not breaching any licenses     that we have <font color="blue">entered into with</font> regard to our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>Others have filed, and in the future are likely to file, patent <font color="blue">application</font>s     <font color="blue">covering genes</font> or <font color="blue">gene fragments</font> or <font color="blue">corresponding proteins</font> or peptides that     we may wish to <font color="blue">utilize with</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font>, or products that     are  similar to products developed with the use of our <font color="blue">technologies</font> or     <font color="blue">alternative</font>  methods  of  <font color="blue">generating</font>  gene  <font color="blue">diversity</font></td>
    </tr>
    <tr>
      <td>If these patent     <font color="blue">application</font>s  result in <font color="blue">issued patents</font> and we wish to use the patented     <font color="blue">technology</font>, we would need to obtain a <font color="blue">license from</font> the <font color="blue">third party</font>, which     may not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> assert that we are employing their <font color="blue">proprietary</font> <font color="blue">technology</font>     <font color="blue">without authorization</font></td>
    </tr>
    <tr>
      <td>In particular, our efforts to develop improved,     next-generation protein <font color="blue">pharmaceuticals</font> could lead to <font color="blue">allegations</font> of patent     <font color="blue">infringement by</font> the <font color="blue">parties <font color="blue">commercializing</font></font> other versions of <font color="blue">such proteins</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font> may obtain patents in the future and claim that     our <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font> infringe these patents</td>
    </tr>
    <tr>
      <td>We could     incur  substantial  costs  and  diversion of the time and attention of     <font color="blue">management</font> and <font color="blue">technical personnel</font> in <font color="blue">defending ourselves against</font> any of     these claims or enforcing our patents or other <font color="blue"><font color="blue">intellectual</font> property</font> rights     <font color="blue">against others</font></td>
    </tr>
    <tr>
      <td>Furthermore, parties making claims <font color="blue">against us may</font> be able to     obtain injunctive or other <font color="blue">equitable relief</font> that could <font color="blue">effective</font>ly block our     ability to further develop, <font color="blue">commercialize</font> and <font color="blue">sell products</font></td>
    </tr>
    <tr>
      <td>In addition, in     the  event of a successful claim of <font color="blue">infringement against us</font>, we may be     required to pay damages and obtain one or more licenses from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain these <font color="blue">licenses at</font> a <font color="blue">reasonable cost</font>, if at all</td>
    </tr>
    <tr>
      <td>In that event, we <font color="blue">could encounter delays</font> in <font color="blue">product introductions while</font> we     attempt to develop <font color="blue">alternative</font> methods or products, or be required to cease     <font color="blue"><font color="blue">commercializing</font> affected products</font></td>
    </tr>
    <tr>
      <td>We  monitor the <font color="blue">public <font color="blue">disclosure</font>s</font> of other companies operating in our     industry regarding their technological <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>If we determine     that these <font color="blue">efforts violate</font> our <font color="blue"><font color="blue">intellectual</font> property</font> or other rights, we     intend to take <font color="blue">appropriate</font> action, <font color="blue">which could</font> include <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any     action we take could result in substantial costs and diversion of <font color="blue">management</font>     and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>Furthermore, the outcome of any action we take to     protect our <font color="blue">rights may</font> not be resolved in our favor</td>
    </tr>
    <tr>
      <td>Budget or cash <font color="blue">constraints</font> may force us to delay or terminate our efforts to     develop certain products and could <font color="blue">prevent us from</font> executing our business     plan,  meeting our stated timetables and <font color="blue">commercializing</font> our potential     products as quickly as possible</td>
    </tr>
    <tr>
      <td>Because we are an <font color="blue">emerging company with</font> limited resources, and because the     research and <font color="blue">development</font> of <font color="blue">pharmaceuticals</font> is a long and <font color="blue">expensive process</font>,     we <font color="blue">must regularly assess</font> the <font color="blue">most efficient allocation</font> of our research and     <font color="blue">development</font> resources</td>
    </tr>
    <tr>
      <td>Accordingly, we may choose to delay or terminate our     research  and <font color="blue">development</font> efforts for a <font color="blue">promising product candidate</font> to     allocate those resources to another program, <font color="blue">which could</font> cause us to fall     behind  our  initial  timetables  for  <font color="blue">development</font> and <font color="blue">prevent us from</font>     <font color="blue">commercializing</font> <font color="blue">product <font color="blue">candidates</font></font> as quickly as possible</td>
    </tr>
    <tr>
      <td>As a result, we     may not be able to fully realize the value of some of our <font color="blue">product <font color="blue">candidates</font></font>     in a <font color="blue">timely manner</font>, since they will be delayed in reaching the market, or     may not reach the <font color="blue">market at</font> all</td>
    </tr>
    <tr>
      <td>We  are  continuing our efforts to <font color="blue">contain costs</font></td>
    </tr>
    <tr>
      <td>On June 16, 2005, we     announced a reduction in force of approximately 16prca of our personnel, across     both our research and <font color="blue"><font color="blue">administrative</font> functions</font></td>
    </tr>
    <tr>
      <td>This reduction in force was     a part of our efforts to focus our <font color="blue">resources on</font> product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>As a     result of the reduction in force, we recorded <font color="blue">termination</font> costs of dlra807cmam000     during 2005, comprised primarily of involuntary <font color="blue">termination</font> benefits</td>
    </tr>
    <tr>
      <td>We     continue to believe <font color="blue">strict cost containment</font> in the near term is essential if     our <font color="blue">current funds</font> are to be sufficient to allow us to continue our currently     planned <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">assess market <font color="blue">conditions</font> on</font> an <font color="blue">ongoing basis</font> and plan     to take <font color="blue">appropriate</font> actions as required</td>
    </tr>
    <tr>
      <td>However, we may not be able to     <font color="blue">effective</font>ly contain our costs and achieve an <font color="blue">expense structure commensurate</font>     with our business <font color="blue">activities</font> and revenues</td>
    </tr>
    <tr>
      <td>As a result, we have inadequate     levels of cash for future <font color="blue">operations</font> or for future capital <font color="blue">requirements</font>,     <font color="blue">which could</font> <font color="blue"><font color="blue">significant</font>ly</font> harm our ability to operate the business</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> capital in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> capital is not     available, we may have to curtail or cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We anticipate that <font color="blue">existing cash</font> and <font color="blue">cash equivalents</font> and <font color="blue">income earned</font>     thereon, <font color="blue">together with</font> anticipated <font color="blue">revenues from</font> <font color="blue"><font color="blue">collaboration</font>s</font> and grants,     <font color="blue">will enable us</font> to maintain our currently planned <font color="blue">operations</font> for at least                                           20     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>the next twelve months</td>
    </tr>
    <tr>
      <td>However, our current plans and <font color="blue">assumptions may</font>     change,  and  our  capital <font color="blue">requirements</font> may increase in <font color="blue">future periods</font>     <font color="blue">depending on</font> many factors, including payments received <font color="blue">under <font color="blue">collaborative</font></font>     <font color="blue">agreement</font>s  and  <font color="blue">government</font>  grants,  the  progress  and  scope of our     <font color="blue">collaborative</font> and in<font color="blue">dependent</font> research and <font color="blue">development</font> projects, the extent     to which we advance products into <font color="blue">clinical trials</font> with our own resources,     the effect of any <font color="blue"><font color="blue">acquisition</font>s</font>, and the filing, prosecution and <font color="blue">enforcement</font>     of  patent claims</td>
    </tr>
    <tr>
      <td>Changes may also occur that <font color="blue">would consume available</font>     capital resources <font color="blue"><font color="blue">significant</font>ly</font> sooner than we expect</td>
    </tr>
    <tr>
      <td>We have <font color="blue">no committed sources</font> of capital and do not know whether <font color="blue">additional</font>     <font color="blue">financing will</font> be available when needed, or, if available, that the terms     will be favorable to us or our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> funds are not     available, we may be forced to delay or <font color="blue">terminate research</font> or preclinical     <font color="blue">development</font> programs, <font color="blue">clinical trials</font>, if any, or the <font color="blue">commercialization</font> of     products,  if  any,  resulting from our <font color="blue">technologies</font>, curtail or cease     <font color="blue">operations</font> or obtain funds through <font color="blue">collaborative</font> and <font color="blue">licensing arrangements</font>     that may require us to <font color="blue">relinquish commercial rights</font> or <font color="blue">potential markets</font>, or     <font color="blue">grant licenses on terms</font> that are not favorable to us</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are     not available, we will not be able to <font color="blue">successfully</font> execute our business plan     or continue our business</td>
    </tr>
    <tr>
      <td>Many potential <font color="blue">competitors</font> who have <font color="blue">greater resources</font> and experience than we     do may develop products and <font color="blue">technologies</font> that make <font color="blue">ours obsolete</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> industry</font> is <font color="blue">characterized by rapid technological</font> change,     and  the area of <font color="blue">gene research</font> is a <font color="blue">rapidly evolving field</font></td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">success will depend on</font> our ability to maintain a <font color="blue">competitive position</font> with     respect to <font color="blue">technological advances</font></td>
    </tr>
    <tr>
      <td>Rapid technological <font color="blue">development</font> by others     may result in our products and <font color="blue">technologies</font> becoming obsolete</td>
    </tr>
    <tr>
      <td>We face, and <font color="blue">will continue</font> to face, intense <font color="blue">competition</font> from both large and     small <font color="blue">bio<font color="blue">technology</font></font> companies, as well as academic and <font color="blue">research institutions</font>     and  <font color="blue">government</font> agencies, that are pursuing competing <font color="blue">technologies</font> for     modifying DNA and proteins</td>
    </tr>
    <tr>
      <td>These companies and <font color="blue">organizations may</font> develop     <font color="blue">technologies</font>  that  are <font color="blue">alternative</font>s to our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Further, our     <font color="blue">competitors</font> in the <font color="blue">protein optimization field may</font> be more <font color="blue">effective</font> at     <font color="blue">implementing</font> their <font color="blue">technologies</font> to develop <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Some of     these <font color="blue">competitors</font> have entered into <font color="blue"><font color="blue"><font color="blue">collaboration</font>s</font> with</font> leading companies     within our target markets to produce <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Any  products that we develop through our <font color="blue">technologies</font> will compete in     multiple, highly competitive markets may fail to achieve <font color="blue">market acceptance</font>,     <font color="blue">which would impair</font> our ability to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Most of the companies     and <font color="blue">organizations competing with us</font> in the markets for <font color="blue">such product</font>s have     greater capital resources, research and <font color="blue">development</font> and marketing staff and     <font color="blue">facilities</font> and <font color="blue">capabilities</font>, and greater experience in modifying DNA and     proteins,  obtaining  <font color="blue">regulatory</font> approvals, <font color="blue">manufacturing</font> products and     marketing</td>
    </tr>
    <tr>
      <td>Our  product  <font color="blue">candidates</font>, even if <font color="blue">approved by</font> the FDA or a     comparable foreign <font color="blue">regulatory</font> agency, may fail to achieve <font color="blue">market acceptance</font>,     <font color="blue">which would impair</font> our ability to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Accordingly,  our  <font color="blue">competitors</font> may be able to develop <font color="blue">technologies</font> and     products more easily, which would render our <font color="blue">technologies</font> and products and     those of our <font color="blue">collaborators</font> obsolete and <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legislative </font>actions, recent and <font color="blue">potential new <font color="blue">accounting pronouncements</font></font> and     <font color="blue">higher <font color="blue">compliance costs</font></font> are likely to <font color="blue">adversely</font> impact our <font color="blue">future financial</font>     position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Recent  changes  in  <font color="blue">financial accounting standards may</font> cause adverse,     unexpected earnings <font color="blue">fluctuations</font> and will <font color="blue">adversely</font> affect our reported     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For example, on <font color="blue">December </font>16, 2004, the Financial     Accounting Standards Board, or FASB, issued FASB Statement Nodtta 123 (revised     2004), “Share-Based Payment,” or SFAS 123(R), which requires all share-based     payments to employees, including grants of <font color="blue"><font color="blue">employee stock option</font>s</font>, to be     recognized in the <font color="blue">income statement based at</font> their <font color="blue">fair values</font></td>
    </tr>
    <tr>
      <td>We adopted     SFAS 123(R) as of January 1, 2006 and we expect the <font color="blue">implementation</font> of SFAS     123(R)’s fair value method to have a <font color="blue">significant</font> impact on our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Such charges will <font color="blue"><font color="blue">significant</font>ly</font> increase our net loss and delay     our  ability  to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The magnitude of the impact of     expensing stock-based <font color="blue">compensation</font> will depend in part                                           21     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>upon  the  timing and amount of <font color="blue">future equity <font color="blue">compensation</font> awards</font></td>
    </tr>
    <tr>
      <td>New     <font color="blue">accounting pronouncements</font> and <font color="blue">varying interpretations</font> of <font color="blue">such pronouncements</font>     have occurred <font color="blue">with frequency</font> in the <font color="blue">recent past</font> and may occur in the future</td>
    </tr>
    <tr>
      <td>In addition, we may make changes in our <font color="blue">accounting policies</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with changing <font color="blue">regulations</font> regarding <font color="blue">corporate governance</font> and     <font color="blue">public <font color="blue">disclosure</font> will also</font> result in <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>laws,     <font color="blue">regulations</font>  and standards relating to <font color="blue">corporate governance</font> and public     <font color="blue">disclosure</font>,  including  the Sarbanes-Oxley Act of 2002 and related SEC     <font color="blue">regulations</font> and <font color="blue">Nasdaq National Market </font>listing <font color="blue">requirements</font>, have created     <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font> and <font color="blue">compliance costs</font> are increasing     as a result of this <font color="blue">uncertainty</font> and other factors</td>
    </tr>
    <tr>
      <td>We are committed to     maintaining <font color="blue">high standards</font> of <font color="blue">corporate governance</font> and public <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>As     a result, we intend to invest all <font color="blue">reasonably</font> <font color="blue">necessary</font> resources to comply     with  evolving standards, and this <font color="blue">investment</font> will result in increased     general and <font color="blue">administrative</font> expenses and may cause a diversion of <font color="blue">management</font>     time  and  attention  from revenue-<font color="blue">generating</font> <font color="blue">activities</font> to compliance     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If  we  do not attract and retain <font color="blue">key employees</font>, our business could be     impaired</td>
    </tr>
    <tr>
      <td>To be successful and achieve our <font color="blue">objectives</font>, we <font color="blue">must attract</font> and retain     <font color="blue">qualified scientific</font> and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in     attracting and retaining <font color="blue">qualified personnel</font>, particularly at the <font color="blue">management</font>     level, our business could be impaired</td>
    </tr>
    <tr>
      <td>We have <font color="blue">been successful</font> in hiring and     retaining  key  personnel  in  the  past; however, we face <font color="blue">significant</font>     <font color="blue">competition</font> for experienced, <font color="blue">management</font> level personnel</td>
    </tr>
    <tr>
      <td>Although we believe     have  <font color="blue">been successful</font> in attracting and retaining <font color="blue">qualified personnel</font>,     <font color="blue">competition</font>  for  experienced <font color="blue">management</font> personnel and <font color="blue">scientists from</font>     <font color="blue">numerous companies</font> and academic and other <font color="blue">research institutions</font> may limit     our ability to do so in the future on acceptable terms</td>
    </tr>
    <tr>
      <td>Failure to attract     and  retain personnel could <font color="blue">prevent us from</font> pursuing <font color="blue"><font color="blue">collaboration</font>s</font> or     developing our products or core <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The operation of <font color="blue"><font color="blue">international</font> locations may increase</font> operating expenses and     divert <font color="blue">management</font> attention</td>
    </tr>
    <tr>
      <td>We  conduct  certain of our <font color="blue">operations</font> through Maxygen ApS, our <font color="blue">Danish     </font>subsidiary</td>
    </tr>
    <tr>
      <td><font color="blue">Operation  </font>as an <font color="blue">international</font> entity requires <font color="blue">additional</font>     <font color="blue">management</font> attention and resources</td>
    </tr>
    <tr>
      <td>We have limited experience in operating     <font color="blue">international</font>ly  and  in  conforming our <font color="blue">operations</font> to <font color="blue">local cultures</font>,     standards and policies</td>
    </tr>
    <tr>
      <td>The costs of operating <font color="blue">international</font>ly are expected     to continue to exceed our <font color="blue">international</font> revenues, if any, for at least the     next  <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>As we continue to operate <font color="blue">international</font>ly, we are     subject to risks of doing business <font color="blue">international</font>ly, including the following:           ·   <font color="blue">regulatory</font> <font color="blue">requirements</font> that may limit or prevent the offering of our     products in <font color="blue">local jurisdictions</font>;           ·   <font color="blue">local legal</font> and <font color="blue">government</font>al limitations on company-wide employee     benefit practices, such as the operation of our <font color="blue">employee stock option</font> plan     in <font color="blue">local jurisdictions</font>;           ·   <font color="blue">government</font> limitations on research and/or research involving     <font color="blue">genetically engineered products</font> or processes;           ·   <font color="blue"><font color="blue">difficult</font>ies</font> in staffing and managing foreign <font color="blue">operations</font>;           ·   <font color="blue">currency exchange risks</font>; and           ·   <font color="blue">potentially</font> adverse tax consequences</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>could result in dilution, operating <font color="blue"><font color="blue">difficult</font>ies</font> and other     <font color="blue">harmful consequences</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">appropriate</font> <font color="blue">opportunities</font> present themselves, we may acquire <font color="blue">businesses</font>     or <font color="blue">technologies</font> that <font color="blue">complement</font> our <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>The process of <font color="blue">integrating</font>     any  <font color="blue">acquisition</font>  may  create  unforeseen  operating  <font color="blue"><font color="blue">difficult</font>ies</font> and     <font color="blue">expenditures</font> and is <font color="blue">itself risky</font></td>
    </tr>
    <tr>
      <td>The areas where we may face <font color="blue"><font color="blue">difficult</font>ies</font>     include:           ·   diversion of <font color="blue">management</font> time (both ours and that of the acquired     company) from focus on operating the <font color="blue">businesses</font> to issues of <font color="blue">integration</font>     during the period of <font color="blue">negotiation through</font> closing and <font color="blue">further diversion</font> of     such time after closing;                                           22     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>  ·   decline in <font color="blue">employee morale</font> and <font color="blue">retention issues</font> resulting from changes     in <font color="blue">compensation</font>, reporting <font color="blue">relationship</font>s, future prospects, or the direction     of the business;           ·   the need to integrate each company’s accounting, <font color="blue">management</font>     information, <font color="blue">human resource</font> and other <font color="blue">administrative</font> systems to permit     <font color="blue">effective</font> <font color="blue">management</font> and the lack of control if such <font color="blue">integration</font> is delayed     or not implemented; and           ·   the need to implement controls, procedures and policies <font color="blue">appropriate</font>     for a <font color="blue">larger public company</font> in companies that before <font color="blue">acquisition</font> had been     smaller, private companies</td>
    </tr>
    <tr>
      <td>We do not have extensive experience in managing this <font color="blue">integration</font> process</td>
    </tr>
    <tr>
      <td>Moreover, the anticipated benefits of any or all of these <font color="blue"><font color="blue">acquisition</font>s</font> may     not be realized</td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">acquisition</font>s</font> could result in <font color="blue">potentially</font> dilutive issuances of equity     securities, the incurrence of debt, contingent liabilities or <font color="blue">amortization</font>     expenses related to <font color="blue">intangible assets</font>, any of <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">acquisition</font>s</font> may require us to obtain <font color="blue">additional</font> equity or debt     financing, which may not be <font color="blue">available on</font> favorable terms or at all</td>
    </tr>
    <tr>
      <td>Even if     available, this <font color="blue">financing may</font> be dilutive</td>
    </tr>
    <tr>
      <td>Our stock price has been, and <font color="blue">may continue</font> to be, <font color="blue">extremely volatile</font>, and an     <font color="blue">investment</font> in our <font color="blue">stock could decline</font> in value</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font>s of <font color="blue">life science company stocks</font> in general, and ours in     particular, have experienced <font color="blue">significant</font> price <font color="blue">fluctuations</font> in the last     <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>During the twelve-month period ended <font color="blue">December </font>31, 2005, the     price of our <font color="blue"><font color="blue">common stock</font> on</font> the <font color="blue">Nasdaq National Market </font>ranged from dlra6dtta49 to     dlra12dtta64</td>
    </tr>
    <tr>
      <td>The <font color="blue">valuations</font> of many <font color="blue">life <font color="blue">science companies</font> without product</font>     revenues and earnings, including ours, are <font color="blue">based on valuation standards such</font>     as price to <font color="blue">sales ratios</font> and progress in product <font color="blue">development</font> or clinical     trials</td>
    </tr>
    <tr>
      <td>Trading <font color="blue">prices based on</font> these <font color="blue">valuations</font> may not be sustained</td>
    </tr>
    <tr>
      <td>Any     negative change in the public’s perception of the prospects of <font color="blue">bio<font color="blue">technology</font></font>     or <font color="blue">life <font color="blue">science companies</font> could depress</font> our <font color="blue">stock price regardless</font> of our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">broad market</font> and <font color="blue">industry factors may decrease</font>     the <font color="blue">trading price</font> of our <font color="blue">common stock</font>, regardless of our performance</td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">stock price could</font> be subject to wide <font color="blue">fluctuations</font> in response     to factors including the following:           ·   our failure to meet our publicly announced revenue and/or expense     projections and/or product <font color="blue">development</font> timetables;           ·   adverse results or delays in preclinical <font color="blue">development</font> or clinical     trials;           ·   any <font color="blue">decisions</font> to <font color="blue">discontinue</font> or delay <font color="blue">development</font> programs or clinical     trials;           ·   <font color="blue">announcements</font> of <font color="blue">new technological innovations</font> or <font color="blue">new products</font> by us     or our <font color="blue">competitors</font>;           ·   <font color="blue">conditions</font> or trends in the <font color="blue">bio<font color="blue">technology</font></font> and life science industries;           ·   changes in the market <font color="blue">valuations</font> of other <font color="blue">bio<font color="blue">technology</font></font> or life     <font color="blue">science companies</font>;           ·   <font color="blue">development</font>s in domestic and <font color="blue">international</font> <font color="blue">government</font>al policy or     <font color="blue">regulations</font>;           ·   <font color="blue">announcements</font> by us or our <font color="blue">competitors</font> of <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font>,     strategic partnerships, joint ventures or <font color="blue">capital commitments</font>;           ·   <font color="blue">development</font>s in or <font color="blue">challenges</font> relating to patent or other <font color="blue">proprietary</font>     rights; and           ·   sales of our <font color="blue">common stock</font> or other securities in the <font color="blue">open market</font></td>
    </tr>
    <tr>
      <td>In the past, <font color="blue">stockholders</font> have often instituted securities class action     <font color="blue">litigation</font> after periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s     securities</td>
    </tr>
    <tr>
      <td>If a stockholder files a securities class action suit against     us, we could incur substantial legal fees and our <font color="blue">management</font>’s attention and     resources would be diverted from operating our business to respond to the     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>Substantial sales of shares may <font color="blue">adversely</font> impact the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">stockholders</font> sell substantial amounts of our <font color="blue">common stock</font>, including     <font color="blue">shares issued upon</font> the exercise of <font color="blue">outstanding options</font>, the <font color="blue">market price</font> of     our <font color="blue">common stock</font> may decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> <font color="blue">trading volume</font> is low and     thus the <font color="blue">market price</font> of our <font color="blue">common stock</font> is <font color="blue">particularly sensitive</font> to     <font color="blue">trading volume</font></td>
    </tr>
    <tr>
      <td>Our low <font color="blue">trading volume</font> may also make it more <font color="blue">difficult</font> for     us to <font color="blue">sell equity</font> or equity related securities in the future at a time and     price that we deem <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>sales of our <font color="blue">common stock</font> may     <font color="blue">adversely</font> impact the then-prevailing <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Some of our existing <font color="blue">stockholders</font> can exert control over us, and may not     make <font color="blue">decisions</font> that are in the <font color="blue">best interests</font> of all <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, our <font color="blue">executive officers</font> and <font color="blue">directors</font>, <font color="blue">together with</font>     <font color="blue">GlaxoSmithKline </font>plc, controlled approximately 28prca of our <font color="blue">outstanding common</font>     stock</td>
    </tr>
    <tr>
      <td>As  a  result,  these  <font color="blue">stockholders</font>, if they act together, and     <font color="blue">GlaxoSmithKline </font>plc, which owns approximately 18prca of our <font color="blue">outstanding common</font>     stock, by itself, could exert a <font color="blue">significant</font> degree of <font color="blue">influence over</font> our     <font color="blue">management</font> and affairs and <font color="blue">over matters</font> requiring <font color="blue">stockholder approval</font>,     including the election of <font color="blue">directors</font> and approval of <font color="blue">significant</font> corporate     <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">concentration</font> of <font color="blue">ownership may delay</font> or     prevent a change in control of our company and <font color="blue">might affect</font> the <font color="blue">market price</font>     of our <font color="blue">common stock</font>, even when a change may be in the <font color="blue">best interests</font> of all     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, the interests of this <font color="blue">concentration</font> of ownership     may  not  <font color="blue">always coincide with</font> our interests or the interests of other     <font color="blue">stockholders</font> and <font color="blue">accordingly</font>, they could cause us to enter into <font color="blue">transactions</font>     or <font color="blue">agreement</font>s that we would not otherwise consider</td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of     <font color="blue">ownership could also depress</font> our stock price</td>
    </tr>
  </tbody>
</table>